Introduced
by
To impose new rules, restrictions and disclosure requirements on health insurers and pharmacy benefit managers selling and marketing prescription drugs to hospitals and clinics that federal rules make eligible for discounts due to treating above-average numbers of Medicaid patients. These providers are not required to pass the savings along to patients. Among other changes the bill would prohibit insurers from requiring patient co-payments for a drug that are higher than the medical provider's cost.
Referred to the Committee on Health Policy
Reported without amendment
With the recommendation that the substitute (H-3) be adopted and that the bill then pass.
Passed in the House 106 to 1 (details)
Referred to the Committee on Health Policy and Human Services
Reported without amendment
With the recommendation that the bill pass.
Passed in the Senate 38 to 0 (details)
To impose new rules, restrictions and disclosure requirements on health insurers and pharmacy benefit managers selling and marketing prescription drugs to hospitals and clinics that federal rules make eligible for discounts due to treating above-average numbers of Medicaid patients. These providers are not required to pass the savings along to patients. Among other changes the bill would prohibit insurers from requiring patient co-payments for a drug that are higher than the medical provider's cost.
Passed in the House 104 to 1 (details)
To concur with the Senate-passed version of the bill.
